#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13206	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2160	606.4	0	.	n	.	0	C326T	SNP	326	326	C	567	567	T	758	T,C	369,319	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	13206	16S	1529	1529	99.93	16S.l6.c4.ctg.1	2160	606.4	1	SNP	n	C1184T	0	.	.	1184	1184	C	1425	1425	C	809	C,T	745,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23596	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3553	660.9	0	.	n	.	0	T695C	SNP	695	695	T	943	943	C	719	C	659	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23596	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3553	660.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1585	1585	A	820	A,G	761,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23596	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3553	660.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2219	2219	C	774	C,T	719,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23596	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3553	660.9	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2845	2845	T	754	T,C	700,7	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23596	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3553	660.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2293	2293	A	723	A	679	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	1746	folP	852	852	100.0	folP.l15.c4.ctg.1	1579	110.1	1	SNP	p	R228S	1	.	.	682	684	AGC	999	1001	AGC	179;173;178	A;G;C,T	164;159;161,1	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4708	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3350	139.8	1	SNP	p	S91F	0	.	.	271	273	TCC	509	511	TCC	143;143;145	T;C;C	132;131;137	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4708	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3350	139.8	1	SNP	p	D95N	0	.	.	283	285	GAC	521	523	GAC	158;156;157	G;A;C	147;146;147	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	4708	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3350	139.8	1	SNP	p	D95G	0	.	.	283	285	GAC	521	523	GAC	158;156;157	G;A;C	147;146;147	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	1466	mtrR	633	633	100.0	mtrR.l15.c17.ctg.1	1355	107.9	1	SNP	p	G45D	1	.	.	133	135	GAC	432	434	GAC	187;187;189	G;A;C	174;171;177	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	768	mtrR_promoter	250	250	100.0	mtrR_promoter.l6.c4.ctg.1	979	78.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4758	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2809	168.6	1	SNP	p	D86N	0	.	.	256	258	GAC	538	540	GAC	223;224;222	G;A;C,T	212;203;208,1	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4758	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2809	168.6	1	SNP	p	S87W	0	.	.	259	261	AGT	541	543	AGT	221;219;221	A;G;T	208;208;209	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4758	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2809	168.6	1	SNP	p	S87R	0	.	.	259	261	AGT	541	543	AGT	221;219;221	A;G;T	208;208;209	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4758	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2809	168.6	1	SNP	p	S87I	0	.	.	259	261	AGT	541	543	AGT	221;219;221	A;G;T	208;208;209	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	4758	parC	2304	2304	100.0	parC.l15.c17.ctg.1	2809	168.6	1	SNP	p	S88P	0	.	.	262	264	TCC	544	546	TCC	219;222;219	T;C;C	205;210;205	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3908	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2616	148.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1545	1547	GGC	184;184;182	G;G;C,T	172;174;170,2	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1229	1231	GCA	178;180;180	G,T;C;A	165,1;165;169	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1232	1234	ATC	181;178;179	A;T;C	169;164;166	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1244	1246	GTG	173;172;172	G;T;G	162;157;158	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1244	1246	GTG	173;172;172	G;T;G	162;157;158	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1748	1750	ACC	152;152;151	A;C;C	134;140;139	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1802	1804	GCG	158;159;157	G;C;G	136;124;126	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1802	1804	GCG	158;159;157	G;C;G	136;124;126	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1925	1927	GGC	140;138;138	G;G;C,T	128;128;126,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1934	1936	GGC	138;137;135	G;G;C	126;122;122	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	3426	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2344	145.6	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1952	1954	CCG	135;134;137	C,G;C,G;GCCC,GGGCCCC	103,1;104,1;95,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4914	ponA	2397	2397	99.96	ponA.l15.c30.ctg.1	3120	156.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2142	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1818	117.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	541	541	C	150	C	132	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	G38E	NONSYN	112	114	GGA	365	367	GAA	193;189;188	G;A;A	176;172;173	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	S46G	NONSYN	136	138	AGC	389	391	GGC	184;179;180	G;G;C	174;173;172	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	395	397	GGA	185;185;188	G;G;A	177;176;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	512	514	GCT	191;191;190	G;C;T	178;177;174	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	518	520	AGC	191;187;189	A;G;C	174;173;177	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	610	611	CG	190;186	C;G	175;171	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	613	615	CAG	184;184;182	C;A;G	172;171;171	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	617	619	AAA	182;184;185	A;A;A	172;173;175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	680	682	GAA	194;195;194	G;A;A	185;187;186	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	704	706	GCA	201;202;201	G;C;A	183;186;183	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	Q187R	NONSYN	559	561	CAA	812	814	CGA	211;207;207	C;G;A	190;186;185	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	A215T	NONSYN	643	645	GCT	896	898	ACT	187;187;186	A;C;T	176;173;175	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	Y216H	NONSYN	646	648	TAT	899	901	CAT	188;186;183	C;A;T	177;177;174	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	I218M	NONSYN	652	654	ATA	905	907	ATG	186;187;186	A;T;G	175;177;174	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	T256A	NONSYN	766	768	ACA	1019	1021	GCA	211;211;207	G;C;A	196;196;192	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	W257T	NONSYN	769	771	TGG	1022	1024	ACG	204;201;201	A;C;G	190;188;187	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	S258R	NONSYN	772	774	AGT	1025	1027	AGG	201;201;202	A;G;G,T	188;188;188,1	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	A259V	NONSYN	775	777	GCT	1028	1030	GTT	200;202;205	G;T;T	187;188;190	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	L279V	NONSYN	835	837	TTA	1088	1090	GTA	213;214;215	G,T;T;A	188,1;189;193	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	S292T	NONSYN	874	876	TCT	1127	1129	ACT	197;196;196	A,T;C;T	177,1;181;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	H294D	NONSYN	880	882	CAT	1133	1135	GAT	193;193;196	G,T;A;T	175,1;173;180	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	S295D	NONSYN	883	885	AGT	1136	1138	GAT	195;194;195	G;A;T	181;175;179	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1142	1144	AAC	198;199;197	A,G;A;C	181,1;184;181	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	0	.	p	.	0	Y298H	NONSYN	892	894	TAC	1145	1147	CAC	200;197;197	C,T;A;C	181,1;179;180	.	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	1	SNP	p	G120K	1	.	.	358	360	AAG	610	612	CGG	190;186;183	C;G;G	175;171;171	porB1b.WHO_L_01891c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	1	SNP	p	A121D	1	.	.	361	363	GAC	613	616	CGC	184;182;183	C;G;C	172;171;171	porB1b.WHO_L_01891c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_L_01891c	porB1b.WHO_L_01891c	1	1	539	2410	porB1b	1047	1047	96.56	porB1b.l15.c30.ctg.1	1427	166.8	1	SNP	p	D121N	0	.	.	361	363	GAC	613	616	CGC	184;182;183	C;G;C	172;171;171	porB1b.WHO_L_01891c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9012	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4863	184.6	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1970	1972	AAT	181;183;184	A,C;A;T	171,1;174;173	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	986	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	1201	81.9	1	SNP	p	V57M	1	.	.	169	171	ATG	641	643	ATG	196;196;201	A;T;G	188;188;192	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
